Leonard Lado, MD
Psychiatry · Bonita Springs, FLNPI 1487642997
Payments from drug & device makers
Across 323 payments — averaging $125.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$28K
- Neuronetics, Inc.$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$754
- Otsuka America Pharmaceutical, Inc.$588
- plus $3K from 17 others
What the payments were for
- Food & beverage$9,28376%
- Education$110%
- Other$3,00024%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $28,377 |
| Neuronetics, Inc. | 21 | $4,194 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 64 | $1,846 |
| AbbVie(2 entities) | 50 | $1,585 |
| Teva Pharmaceuticals USA, Inc. | 29 | $754 |
| Otsuka America Pharmaceutical, Inc. | 20 | $588 |
| Sunovion Pharmaceuticals Inc. | 18 | $456 |
| Alkermes, Inc. | 14 | $394 |
| Johnson & Johnson | 12 | $375 |
| Axsome Therapeutics, Inc. | 11 | $352 |
| Neurocrine Biosciences, Inc. | 12 | $318 |
| Almatica Pharma LLC | 19 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $281 |
| Indivior Inc. | 12 | $263 |
| Lundbeck LLC | 4 | $119 |
| Vanda Pharmaceuticals Inc. | 5 | $118 |
| Corium, LLC | 4 | $102 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Noven Therapeutics, LLC | 2 | $31 |
| Livanova USA, Inc. | 1 | $24 |
| Orexo US, Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$3,269
- CAPLYTA$709
- VRAYLAR$608
- NEUROSTAR TMS THERAPY$322
- ABILIFY MAINTENA$128
- ABILIFY ASIMTUFII$128
- Auvelity$125
- REXULTI$125
- Austedo XR$121
- LATUDA$115
- SPRAVATO$105
How this compares
$40,644 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 85 | $137,703 |
| Austedo XrDeutetrabenazine | 15 | $108,278 |
| RexultiBrexpiprazole | 50 | $89,409 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 459 | $74,743 |
| CaplytaLumateperone Tosylate | 26 | $46,361 |
| Invega SustennaPaliperidone Palmitate | 12 | $29,199 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 296 | $9,820 |
| Paliperidone ErPaliperidone | 41 | $9,743 |
| TrintellixVortioxetine Hydrobromide | 21 | $9,542 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,016 |
| Lurasidone Hcl | 46 | $5,874 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $5,592 |
| Buprenorphine Hcl | 137 | $5,484 |
| BelsomraSuvorexant | 12 | $5,051 |
| Clonazepam | 454 | $4,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,585 | $137,70385 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $754 | $108,27815 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $588 | $89,40950 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,846 | $46,36126 claims |
| Johnson & JohnsonInvega Sustenna | $375 | $29,19912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $281 | $15,55837 claims |
| MerckBelsomra | $28,377 | $5,05112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Bonita Springs
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.